A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

IsraelTerminatedPHASE2

Conditions

Non-segmental Vitiligo

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Cahaba Dermatology & Skin Health Center ( Site 0127), Birmingham, Alabama, United States

  • Burke Pharmaceutical Research ( Site 0124), Hot Springs, Arkansas, United States

  • The Vitiligo & Pigmentation Institute of Southern California ( Site 0115), Los Angeles, California, United States

  • Indiana University Health University Hospital-Indiana University School of Medicine, Department of (, Indianapolis, Indiana, United States

  • Dawes Fretzin Clinical Research Group, LLC ( Site 0106), Indianapolis, Indiana, United States

  • Metro Boston Clinical Partners ( Site 0110), Brighton, Massachusetts, United States

  • Hamzavi Dermatology - Canton ( Site 0101), Canton, Michigan, United States

  • Remington Davis Clinical Research-Outpatient ( Site 0104), Columbus, Ohio, United States

  • Medical University of South Carolina-Dermatology Research ( Site 0114), Charleston, South Carolina, United States

  • International Clinical Research - Tennessee LLC ( Site 0120), Murfreesboro, Tennessee, United States

  • Progressive Clinical Research ( Site 0108), San Antonio, Texas, United States

  • Virginia Clinical Research, Inc. ( Site 0109), Norfolk, Virginia, United States

  • Dermatology Specialists of Spokane ( Site 0126), Spokane, Washington, United States

  • Psoriahue ( Site 0205), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Stat Research S.A. ( Site 0204), Buenos Aires, Buenos Aires F.D., Argentina

  • Centro de Investigaciones Metabólicas (CINME)-Dermatology ( Site 0203), Buenos Aires, Buenos Aires F.D., Argentina

  • Instituto Medico Strusberg ( Site 0208), Córdoba, Córdoba Province, Argentina

  • Hospital Aleman-Dermatologia ( Site 0209), Buenos Aires, Argentina

  • Paratus Clinical Research Woden ( Site 1703), Phillip, Australian Capital Territory, Australia

  • Westmead Hospital-Dermatology ( Site 1701), Westmead, New South Wales, Australia

  • Skin Health Institute Inc.-Trials ( Site 1702), Carlton, Victoria, Australia

  • Sinclair Dermatology ( Site 1704), Melbourne, Victoria, Australia

  • UZ Gent ( Site 0604), Ghent, Oost-Vlaanderen, Belgium

  • UZ Leuven ( Site 0601), Leuven, Vlaams-Brabant, Belgium

  • Enverus Medical Research ( Site 0006), Surrey, British Columbia, Canada

  • Diex Recherche Quebec Inc. ( Site 0008), Québec, Quebec, Canada

  • Centre de Recherche Dermatologique du Quebec metropolitain ( Site 0002), Québec, Quebec, Canada

  • Diex Recherche sherbrooke Inc. ( Site 0007), Sherbrooke, Quebec, Canada

  • Dermisur ( Site 0305), Osorno, Los Lagos Region, Chile

  • Clinical Research Chile SpA ( Site 0304), Valdivia, Los Ríos Region, Chile

  • Clinica Dermacross ( Site 0301), Santiago, Region M. de Santiago, Chile

  • Pontificia Universidad Catolica de Chile-CICUC ( Site 0308), Santiago, Region M. de Santiago, Chile

  • Centro Internacional de Estudios Clinicos (CIEC) ( Site 0302), Santiago, Region M. de Santiago, Chile

  • CliniSalud ( Site 0401), Envigado, Antioquia, Colombia

  • IPS SURA San Diego ( Site 0408), Medellín, Antioquia, Colombia

  • Centro Integral de Reumatología del Caribe ( Site 0405), Barranquilla, Atlántico, Colombia

  • Healthy Medical Center S.A.S ( Site 0403), Zipaquirá, Cundinamarca, Colombia

  • Fundación Valle del Lili ( Site 0412), Cali, Valle del Cauca Department, Colombia

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0803), Nice, Alpes-Maritimes, France

  • CHU de Bordeaux Hop St ANDRE ( Site 0804), Bordeaux, Aquitaine, France

  • Hôpital Edouard Herriot ( Site 0802), Lyon, Auvergne-Rhône-Alpes, France

  • HENRI MONDOR HOSPITAL ( Site 0801), Créteil, Val-de-Marne, France

  • Universitaetsklinikum Erlangen-Hautklinik Studienambulanz ( Site 0905), Erlangen, Bavaria, Germany

  • Universitätsklinikum Münster-Hautklinik ( Site 0904), Münster, North Rhine-Westphalia, Germany

  • Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0901), Berlin, Germany

  • Rambam Health Care Campus-Dermatology ( Site 1002), Haifa, Israel

  • Sheba Medical Center-Dermatology ( Site 1001), Ramat Gan, Israel

  • Nagoya City University Hospital-Dermatology ( Site 2002), Nagoya, Aichi-ken, Japan

  • Osaka University Hospital ( Site 2004), Suita, Osaka, Japan

  • Tokyo Medical University Hospital ( Site 2001), Shinjuku-ku, Tokyo, Japan

  • Cryptex Investigación Clínica S.A. de C.V. ( Site 0515), Cuauhtémoc, Ciudad de México, Mexico City, Mexico

  • Unidad biomedica avanzada monterrey-Clinical Trials ( Site 0504), Monterrey, Nuevo León, Mexico

  • Centro de Atención e Investigación Clínica ( Site 0507), Aguascalientes, Mexico

  • Amsterdam UMC, locatie AMC-Dermatology ( Site 1101), Amsterdam, North Holland, Netherlands

  • Inha University Hospital ( Site 1992), Incheon, South Korea

  • Seoul National University Hospital-Dermatology ( Site 1991), Seoul, South Korea

  • Severance Hospital, Yonsei University Health System-Department of Dermatology ( Site 1993), Seoul, South Korea

  • Hospital Universitario Puerta del Mar ( Site 1302), Cadiz, Andalusia, Spain

  • Hospital Universitari de Bellvitge-Dermatology ( Site 1307), L'Hospitalet de Llobregat, Barcelona, Spain

  • Clinica Universidad de Navarra ( Site 1305), Madrid, Madrid, Comunidad de, Spain

  • Cantonal Hospital St.Gallen ( Site 1402), Sankt Gallen, Canton of St. Gallen, Switzerland

  • UniversitätsSpital Zürich ( Site 1401), Zurich, Canton of Zurich, Switzerland

  • Hacettepe Universite Hastaneleri-Dermatology ( Site 1501), Altindağ, Ankara, Turkey (Türkiye)

  • Ankara Bilkent Şehir Hastanesi-Dermatology ( Site 1502), Ankara, Turkey (Türkiye)

  • Erciyes Universitesi Tıp Fakultesi Hastaneleri-Dermatology and Venereology ( Site 1506), Kayseri, Turkey (Türkiye)

  • Royal London Hospital-Dermatology Research Unit ( Site 1605), London, England, United Kingdom

  • Queen Elizabeth Hospital Birmingham ( Site 1603), Birmingham, Warwickshire, United Kingdom

  • New Cross Hospital ( Site 1601), Wolverhampton, United Kingdom

Study leads
  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC

View source on ClinicalTrials.gov(opens in a new tab)

No study contact email or phone is listed for this trial.